KLCM Advisors Inc. continued to hold its stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,600 shares of the company’s stock at the end of the second quarter. KLCM Advisors Inc.’s holdings in Eli Lilly and were worth $461,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Airain ltd acquired a new position in Eli Lilly and in the 2nd quarter worth about $567,000. Buckingham Asset Management LLC increased its holdings in Eli Lilly and by 21.3% in the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after purchasing an additional 568 shares in the last quarter. BSW Wealth Partners increased its holdings in Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after purchasing an additional 27 shares in the last quarter. Sumitomo Life Insurance Co. increased its stake in shares of Eli Lilly and by 4.4% in the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after buying an additional 1,370 shares during the period. Finally, Mirador Capital Partners LP increased its stake in shares of Eli Lilly and by 5.3% in the second quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after buying an additional 619 shares during the period. 76.61% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on the company. Morgan Stanley increased their price target on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a research note on Wednesday, November 1st. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research note on Thursday, October 26th. Finally, Leerink Swann increased their price target on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $89.97.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 772,003 shares of company stock worth $64,837,441. 0.20% of the stock is owned by corporate insiders.

Shares of Eli Lilly and Company (NYSE LLY) opened at $83.68 on Friday. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The company has a market capitalization of $92,139.64, a PE ratio of 20.46, a P/E/G ratio of 1.85 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the company earned $0.88 EPS. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. research analysts forecast that Eli Lilly and Company will post 4.21 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.49%. Eli Lilly and’s payout ratio is 98.58%.

WARNING: “Eli Lilly and Company (LLY) Position Held by KLCM Advisors Inc.” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/24/eli-lilly-and-company-lly-position-held-by-klcm-advisors-inc.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.